Role of Long Non-coding RNAs and Natural Products in Prostate Cancer: Insights into Key Signaling Pathways

Overview

Journal Funct Integr Genomics

Publisher Springer

Date 2025 Jan 17

PMID 39821470

Authors

Ahmed S Doghish

Sherif S Abdel Mageed

Mohamed Bakr Zaki

Mai A Abd-Elmawla

Ghadir A Sayed

Abdulrahman Hatawsh

Nora M Aborehab

Rewan Moussa

Osama A Mohammed

Mustafa Ahmed Abdel-Reheim

Hanan Elimam

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PC) ranks among the most prevalent cancers in males. Recent studies have highlighted intricate connections between long non-coding RNAs (lncRNAs), natural products, and cellular signaling in PC development. LncRNAs, which are RNA transcripts without protein-coding function, influence cell growth, programmed cell death, metastasis, and resistance to treatments through pathways like PI3K/AKT, WNT/β-catenin, and androgen receptor signaling. Certain lncRNAs, including HOTAIR and PCA3, are associated with PC progression, with potential as diagnostic markers. Natural compounds, such as curcumin and resveratrol, demonstrate anticancer effects by targeting these pathways, reducing tumor growth, and modulating lncRNA expression. For instance, curcumin suppresses HOTAIR levels, hindering PC cell proliferation and invasion. The interaction between lncRNAs and natural compounds may open new avenues for therapy, as these substances can simultaneously impact multiple signaling pathways. These complex interactions offer promising directions for developing innovative PC treatments, enhancing diagnostics, and identifying new biomarkers for improved prevention and targeted therapy. This review aims to map the multifaceted relationship among natural products, lncRNAs, and signaling pathways in PC pathogenesis, focusing on key pathways such as AR, PI3K/AKT/mTOR, WNT/β-catenin, and MAPK, which are crucial in PC progression and therapy resistance. Regulation of these pathways by natural products and lncRNAs could lead to new insights into biomarker identification, preventive measures, and targeted PC therapies.

References

Abd-Elmawla M, Elsamanoudie N, Ismail M, Hammam O, El Magdoub H . The interplay of TapSAKI and NEAT-1 as potential modulators in gentamicin-induced acute kidney injury via orchestrating miR-22-3p/TLR4/MyD88/NF-қB/IL-1 β milieu: Novel therapeutic approach of Betanin. Int Immunopharmacol. 2024; 143(Pt 3):113577. DOI: 10.1016/j.intimp.2024.113577. View

Al Aameri R, Sheth S, Alanisi E, Borse V, Mukherjea D, Rybak L . Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol. PLoS One. 2017; 12(5):e0177198. PMC: 5415196. DOI: 10.1371/journal.pone.0177198. View

Amado N, Predes D, Moreno M, Carvalho I, Mendes F, Abreu J . Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies. Int J Mol Sci. 2014; 15(7):12094-106. PMC: 4139831. DOI: 10.3390/ijms150712094. View

An C, Wang I, Li X, Xia R, Deng F . Long non-coding RNA in prostate cancer. Am J Clin Exp Urol. 2022; 10(3):170-179. PMC: 9301060. View

Angeles A, Heckmann D, Flosdorf N, Duensing S, Sultmann H . The ERG-Regulated Promotes Prostate Cancer Cell Survival via the 14-3-3ε-FOXO Pathway. Mol Cancer Res. 2020; 18(10):1545-1559. DOI: 10.1158/1541-7786.MCR-20-0021. View

Arun G, Diermeier S, Spector D . Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med. 2018; 24(3):257-277. PMC: 5840027. DOI: 10.1016/j.molmed.2018.01.001. View

Ashrafizadeh M, Paskeh M, Mirzaei S, Gholami M, Zarrabi A, Hashemi F . Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022; 41(1):105. PMC: 8939209. DOI: 10.1186/s13046-022-02293-6. View

Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A . Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation. Cancer Metastasis Rev. 2024; 43(1):229-260. DOI: 10.1007/s10555-024-10168-9. View

10.

Barbieri C, Bangma C, Bjartell A, Catto J, Culig Z, Gronberg H . The mutational landscape of prostate cancer. Eur Urol. 2013; 64(4):567-76. PMC: 4342117. DOI: 10.1016/j.eururo.2013.05.029. View

11.

Bhan A, Soleimani M, Mandal S . Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965-3981. PMC: 8330958. DOI: 10.1158/0008-5472.CAN-16-2634. View

12.

Bo S, Lai J, Lin H, Luo X, Zeng Y, Du T . Purpurin, a anthraquinone induces ROS-mediated A549 lung cancer cell apoptosis via inhibition of PI3K/AKT and proliferation. J Pharm Pharmacol. 2021; 73(8):1101-1108. DOI: 10.1093/jpp/rgab056. View

13.

Bu T, Li L, Tian J . Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway. Front Pharmacol. 2023; 14:1269233. PMC: 10565042. DOI: 10.3389/fphar.2023.1269233. View

14.

Cai Q, Dozmorov M, Oh Y . IGFBP-3/IGFBP-3 Receptor System as an Anti-Tumor and Anti-Metastatic Signaling in Cancer. Cells. 2020; 9(5). PMC: 7290346. DOI: 10.3390/cells9051261. View

15.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M . A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147(2):358-69. PMC: 3234495. DOI: 10.1016/j.cell.2011.09.028. View

16.

Chen J, Wang F, Xu H, Xu L, Chen D, Wang J . Long Non-Coding RNA SNHG1 Regulates the Wnt/β-Catenin and PI3K/AKT/mTOR Signaling Pathways EZH2 to Affect the Proliferation, Apoptosis, and Autophagy of Prostate Cancer Cell. Front Oncol. 2020; 10:552907. PMC: 7643000. DOI: 10.3389/fonc.2020.552907. View

17.

Chinison J, Aguilar J, Avalos A, Huang Y, Wang Z, Cameron D . Triptonide Effectively Inhibits Wnt/β-Catenin Signaling via C-terminal Transactivation Domain of β-catenin. Sci Rep. 2016; 6:32779. PMC: 5011721. DOI: 10.1038/srep32779. View

18.

Cuesta C, Arevalo-Alameda C, Castellano E . The Importance of Being PI3K in the RAS Signaling Network. Genes (Basel). 2021; 12(7). PMC: 8303222. DOI: 10.3390/genes12071094. View

19.

Cui Z, Gao H, Yan N, Dai Y, Wang H, Wang M . LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis. Aging (Albany NY). 2021; 13(8):12113-12128. PMC: 8109094. DOI: 10.18632/aging.202919. View

20.

Degirmenci U, Wang M, Hu J . Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells. 2020; 9(1). PMC: 7017232. DOI: 10.3390/cells9010198. View

21.

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H . The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22(9):1775-89. PMC: 3431493. DOI: 10.1101/gr.132159.111. View